In the context of viral infection and cancer, significant potential lies in the use of CRISPR-Cas9 [including other Cas proteins, such as the alternative DNA nuclease Cas12 (181), and RNA nuclease Cas13 (182)] and dCas9-based methods to target NKG2D and its ligands for enhanced immune recognition and elimination. This evidence concerns the gene KLRK1 and cancer.